Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Computational metabolism modeling predicts risk of distant relapse-free survival in breast cancer patients.

Trilla-Fuertes L, Gámez-Pozo A, Díaz-Almirón M, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Nanni P, Zamora P, Espinosa E, Fresno Vara JÁ.

Future Oncol. 2019 Oct;15(30):3483-3490. doi: 10.2217/fon-2018-0698. Epub 2019 Oct 3.

PMID:
31580166
2.

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Arevalillo JM, Ferrer-Gómez M, Navarro H, Maín P, Espinosa E, Pinto Á, Vara JÁF.

BMC Cancer. 2019 Jun 28;19(1):636. doi: 10.1186/s12885-019-5858-z.

3.

Melanoma proteomics suggests functional differences related to mutational status.

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Fortes C, Ferrer-Gómez M, López-Vacas R, Parra Blanco V, Márquez-Rodas I, Soria A, Fresno Vara JÁ, Espinosa E.

Sci Rep. 2019 May 10;9(1):7217. doi: 10.1038/s41598-019-43512-z.

4.

Isotopologue Multipoint Calibration for Proteomics Biomarker Quantification in Clinical Practice.

Chiva C, Pastor O, Trilla-Fuertes L, Gámez-Pozo A, Fresno Vara JÁ, Sabidó E.

Anal Chem. 2019 Apr 16;91(8):4934-4938. doi: 10.1021/acs.analchem.8b05802. Epub 2019 Mar 25.

PMID:
30882204
5.

Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.

Rojas L K, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, Sepúlveda J, Manso L, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Ferrer-Gómez M, Mendiola C, Espinosa E, Sabidó E, Ciruelos E, Vara JÁF.

Ecancermedicalscience. 2019 Jan 15;13:891. doi: 10.3332/ecancer.2019.891. eCollection 2019.

6.

A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.

Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, Díaz-Almirón M, López-Vacas R, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2019 Feb 7;9(1):1538. doi: 10.1038/s41598-018-38364-y.

7.

Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer.

Zapater-Moros A, Gámez-Pozo A, Prado-Vázquez G, Trilla-Fuertes L, Arevalillo JM, Díaz-Almirón M, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jun 12;9(45):27586-27594. doi: 10.18632/oncotarget.25496. eCollection 2018 Jun 12.

8.

Molecular characterization of breast cancer cell response to metabolic drugs.

Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, Díaz-Almirón M, Prado-Vázquez G, Zapater-Moros A, Navarro H, Aras-López R, Dapía I, López-Vacas R, Nanni P, Llorente-Armijo S, Arias P, Borobia AM, Maín P, Feliú J, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jan 8;9(11):9645-9660. doi: 10.18632/oncotarget.24047. eCollection 2018 Feb 9.

9.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

10.

Functional proteomics outlines the complexity of breast cancer molecular subtypes.

Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, Grossmann J, Gayá Moreno F, Gómez Rioja R, Prado-Vázquez G, Zapater-Moros A, Main P, Feliú J, Martínez Del Prado P, Zamora P, Ciruelos E, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2017 Aug 30;7(1):10100. doi: 10.1038/s41598-017-10493-w.

11.

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.

Gámez-Pozo A, Trilla-Fuertes L, Prado-Vázquez G, Chiva C, López-Vacas R, Nanni P, Berges-Soria J, Grossmann J, Díaz-Almirón M, Ciruelos E, Sabidó E, Espinosa E, Fresno Vara JÁ.

PLoS One. 2017 Jun 8;12(6):e0178296. doi: 10.1371/journal.pone.0178296. eCollection 2017.

12.

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases.

Laimito KR, Gámez-Pozo A, Sepúlveda J, Manso L, López-Vacas R, Pascual T, Fresno Vara JA, Ciruelos E.

Ecancermedicalscience. 2016 Apr 11;10:632. doi: 10.3332/ecancer.2016.632. eCollection 2016. Review.

13.

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.

Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, Grossmann J, Castaneda CA, Main P, Díaz-Almirón M, Espinosa E, Ciruelos E, Fresno Vara JÁ.

Cancer Res. 2015 Jun 1;75(11):2243-53. doi: 10.1158/0008-5472.CAN-14-1937. Epub 2015 Apr 16.

14.

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López-Vacas R, Berges-Soria J, López IÁ, Margeli M, Calero JL, Farre XG, Santaballa A, Ciruelos EM, Afonso R, Lao J, Catalán G, Gallego JV, López JM, Bofill FJ, Borrego MR, Espinosa E, Vara JA, Zamora P.

PLoS One. 2014 Oct 20;9(10):e109611. doi: 10.1371/journal.pone.0109611. eCollection 2014.

15.

Shotgun proteomics of archival triple-negative breast cancer samples.

Gámez-Pozo A, Ferrer NI, Ciruelos E, López-Vacas R, Martínez FG, Espinosa E, Vara JÁ.

Proteomics Clin Appl. 2013 Apr;7(3-4):283-91. doi: 10.1002/prca.201200048. Epub 2013 Mar 6.

PMID:
23436753
16.

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A, Martínez-Villanueva M, Iglesias L, García-Carbonero R, Fresno Vara JA, Gámez-Pozo A, Palacios J, Cortés-Funes H, Paz-Ares L, Agulló-Ortuño MT.

Carcinogenesis. 2013 May;34(5):1031-8. doi: 10.1093/carcin/bgt022. Epub 2013 Jan 24.

PMID:
23349018
17.

Gene signatures in breast cancer: current and future uses.

Arranz EE, Vara JÁ, Gámez-Pozo A, Zamora P.

Transl Oncol. 2012 Dec;5(6):398-403. Epub 2012 Dec 1.

18.

MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.

Gámez-Pozo A, Antón-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, García-Domínguez R, de Portugal T, Ramos-Vázquez M, Pérez-Carrión R, Bolós MV, Madero R, Sánchez-Navarro I, Fresno Vara JA, Espinosa Arranz E.

Neoplasia. 2012 Dec;14(12):1144-52.

19.

PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.

Gámez-Pozo A, Sánchez-Navarro I, Calvo E, Agulló-Ortuño MT, López-Vacas R, Díaz E, Camafeita E, Nistal M, Madero R, Espinosa E, López JA, Fresno Vara JÁ.

PLoS One. 2012;7(3):e33752. doi: 10.1371/journal.pone.0033752. Epub 2012 Mar 26.

20.

The present and future of gene profiling in breast cancer.

Espinosa E, Gámez-Pozo A, Sánchez-Navarro I, Pinto A, Castañeda CA, Ciruelos E, Feliu J, Vara JA.

Cancer Metastasis Rev. 2012 Jun;31(1-2):41-6. doi: 10.1007/s10555-011-9327-7. Review.

PMID:
22124734
21.

Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches.

Gámez-Pozo A, Sánchez-Navarro I, Calvo E, Díaz E, Miguel-Martín M, López R, Agulló T, Camafeita E, Espinosa E, López JA, Nistal M, Vara JÁ.

Mol Biosyst. 2011 Aug;7(8):2368-74. doi: 10.1039/c1mb05113j. Epub 2011 May 26.

PMID:
21617801
22.

Gene profiling in breast cancer: time to move forward.

Espinosa E, Vara JÁ, Navarro IS, Gámez-Pozo A, Pinto A, Zamora P, Redondo A, Feliu J.

Cancer Treat Rev. 2011 Oct;37(6):416-21. doi: 10.1016/j.ctrv.2010.12.009. Epub 2011 Feb 1. Review.

PMID:
21277684
23.

An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer.

Sánchez-Navarro I, Gámez-Pozo A, Pinto A, Hardisson D, Madero R, López R, San José B, Zamora P, Redondo A, Feliu J, Cejas P, González Barón M, Angel Fresno Vara J, Espinosa E.

BMC Cancer. 2010 Jun 28;10:336. doi: 10.1186/1471-2407-10-336.

24.

Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues.

Sánchez-Navarro I, Gámez-Pozo A, González-Barón M, Pinto-Marín A, Hardisson D, López R, Madero R, Cejas P, Mendiola M, Espinosa E, Vara JA.

Biotechniques. 2010 May;48(5):389-97. doi: 10.2144/000113388.

25.

MALDI profiling of human lung cancer subtypes.

Gámez-Pozo A, Sánchez-Navarro I, Nistal M, Calvo E, Madero R, Díaz E, Camafeita E, de Castro J, López JA, González-Barón M, Espinosa E, Fresno Vara JA.

PLoS One. 2009 Nov 5;4(11):e7731. doi: 10.1371/journal.pone.0007731.

26.

Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer.

Espinosa E, Sánchez-Navarro I, Gámez-Pozo A, Marin AP, Hardisson D, Madero R, Redondo A, Zamora P, San José Valiente B, Mendiola M, González Barón M, Fresno Vara JA.

PLoS One. 2009 Jun 15;4(6):e5911. doi: 10.1371/journal.pone.0005911.

27.

Pathogenic validation of unique germline intronic variants of RB1 in retinoblastoma patients using minigenes.

Gámez-Pozo A, Palacios I, Kontic M, Menéndez I, Camino I, García-Miguel P, Abelairas J, Pestaña A, Alonso J.

Hum Mutat. 2007 Dec;28(12):1245.

PMID:
18000883

Supplemental Content

Loading ...
Support Center